%0 Journal Article
%T Combined Use of MITRACLIP and Ventricular ASSIST Devices in Cardiogenic Shock: MITRA-ASSIST Registry.
%A Rivero-Santana B
%A Jurado-Roman A
%A Pascual I
%A Li CH
%A Jimenez P
%A Estevez-Loureiro R
%A Cepas-Guillén P
%A Benito-González T
%A Serrador A
%A De La Torre-Hernandez JM
%A Avanzas P
%A Fernandez-Peregrina E
%A Nombela L
%A Caneiro-Queija B
%A Freixas X
%A Fernandez-Vazquez F
%A Amat-Santos I
%A Lee DH
%A Leon V
%A Arzamendi D
%A Moreno R
%A Galeote G
%J J Clin Med
%V 13
%N 15
%D 2024 Jul 28
%M 39124675
%F 4.964
%R 10.3390/jcm13154408
%X Background: Patients with cardiogenic shock (CS) and mitral regurgitation (MI) have a prohibitive risk that contraindicates surgical treatment. Although the feasibility of transcatheter edge-to-edge therapy (TEER) has been demonstrated in this setting, the benefit of the combined use of TEER with mechanical circulatory support devices (MCS) has not been studied. The aim of this study was to evaluate the clinical outcomes of TEER in patients with MCS. Methods: The MITRA-ASSIST study is a retrospective multicentre Spanish registry that included patients with MR and CS who underwent TEER in combination with MCS. The primary endpoint was death from any cause at 12 months. The secondary endpoint was a composite of death from any cause or hospitalisation for heart failure at 12 months. Results: A total of twenty-four patients in nine high-volume Spanish centres (66.2 (51-82) years, 70.8% female, EuroSCORE II 20.4 ± 17.8) were included. Acute ST-elevation myocardial infarction was the main CS aetiology (56%), and the most implanted MCS was the intra-aortic balloon pump (82.6%), followed by ECMO (8.7%), IMPELLACP® (4.3%), or a combination of both (4.3%). Procedural success was 95.8%, with 87.5% in-hospital survival. At 12-month follow-up, 25.0% of patients died, and 33.3% had a composite event of death from any cause or hospitalisation for heart failure. Conclusions: TEER in patients with concomitant CS and MR who require MCS appears to be a promising therapeutic alternative with a high device procedural success rate and acceptable mortality and heart failure readmission rates at follow-up.